Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Factors Associated With Survival After Relapse In Patients With Low-Risk Endometrial Cancer Treated With Surgery Alone

Title: Factors Associated With Survival After Relapse In Patients With Low-Risk Endometrial Cancer Treated With Surgery Alone
Authors: Topfedaisi Ozkan, Nazli; Meydanlı, Mehmet Mutlu; Sarı, Mustafa Erkan; Demirkiran, Fuat; Kahramanoglu, Ilker; Bese, Tugan; Arvas, Macit; Şahin, Hanifi; Haberal, Ali; Celik, Husnu; Coban, Gonca; Oge, Tufan; Yalcin, Omer Tarik; Akbayır, Özgür; Erdem, Baki; Numanoğlu, Ceyhun; Özgül, Nejat; Boyraz, Gökhan; Salman, Mehmet Coşkun; Yüce, Kunter; Dede, Murat; Yenen, Mufit Cemal; Taşkın, Salih; Altın, Duygu; Ortaç, Uğur Fırat; Aydın Ayık, Hülya; Şimşek, Tayup; Güngör, Tayfun; Güngördük, Kemal; Sancı, Muzaffer; Ayhan, Ali
Contributors: Kadın Hastalıkları ve Doğum
Publication Year: 2017
Collection: Hacettepe University Institutional Repository
Description: Objective To determine factors influencing overall survival following recurrence (OSFR) in women with low-risk endometrial cancer (EC) treated with surgery alone. Methods A multicenter, retrospective department database review was performed to identify patients with recurrent “low-risk EC” (patients having less than 50% myometrial invasion [MMI] with grade 1 or 2 endometrioid EC) at 10 gynecologic oncology centers in Turkey. Demographic, clinicopathological, and survival data were collected. Results We identified 67 patients who developed recurrence of their EC after initially being diagnosed and treated for low-risk EC. For the entire study cohort, the median time to recurrence (TTR) was 23 months (95% confidence interval [CI]=11.5–34.5; standard error [SE]=5.8) and the median OSFR was 59 months (95% CI=12.7–105.2; SE=23.5). We observed 32 (47.8%) isolated vaginal recurrences, 6 (9%) nodal failures, 19 (28.4%) peritoneal failures, and 10 (14.9%) hematogenous disseminations. Overall, 45 relapses (67.2%) were loco-regional whereas 22 (32.8%) were extrapelvic. According to the Gynecologic Oncology Group (GOG) Trial-99, 7 (10.4%) out of 67 women with recurrent low-risk EC were qualified as high-intermediate risk (HIR). The 5-year OSFR rate was significantly higher for patients with TTR ≥36 months compared to those with TTR
Document Type: article in journal/newspaper
File Description: text/plain; application/pdf
Language: unknown
Relation: Journal of Gynecologic Oncology; https://doi.org/10.3802/jgo.2017.28.e65; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540724/; http://hdl.handle.net/11655/16658; 28
DOI: 10.3802/jgo.2017.28.e65
Availability: http://hdl.handle.net/11655/16658; https://doi.org/10.3802/jgo.2017.28.e65; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540724/
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.36E12C7A
Database: BASE